🏥Cell and Gene Therapy Catapult enters into partnership with the Japanese Society for Regenerative Medicine

By ES, IPS, medical service

🏥Cell and Gene Therapy Catapult enters into partnership with the Japanese Society for Regenerative Medicine

01 March 2018

Memorandum of Understanding between CGT Catapult and JSRM further enhances the UK’s relationship with regenerative medicine centres in Japan and contributes to the advancement of cell and gene therapies worldwide

On 27th February 2018, The Cell and Gene Therapy Catapult (CGT Catapult) announced it has signed a Memorandum of Understanding (MoU) with the Japanese Society for Regenerative Medicine (JSRM).

This agreement between the CGT Catapult and JSRM, the largest society for regenerative medicine in the world, aims to advance regenerative medicine and cell and gene therapies in both the UK and Japan.

Drug Discovery Today

http://www.drugdiscoverytoday.com/view/47461/cell-and-gene-therapy-catapult-enters-into-partnership-with-the-japanese-society-for-regenerative-medicine/

More from tokioX :

  1. Sapporo Medical Univ： Medical examination of spinal cord injury start-Product for regenerative medicine “Stemilac injection”
  2. Kyoto Univ’s Center for iPS Cell Research and Application, Sumitomo Chemical, and Sumitomo Dainippon Pharma Commence Joint Research on Producing Higher-Quality iPS Cells for Clinical Use
  3. Cancer Therapy: Kyoto University, New Method Detecting Aggressively Attacking Cancer Cells – Human iPS-derived “Killer T Cells”
  4. Parkinson’s Disease: Kyoto Univ conducted transplant surgery using human iPS cells
  5. Kyoto Univ. Eyes Clinical Study on iPS Cell-Derived Platelets
  6. AIST: a gene that creates myocardium – Tbx 6 is newly discovered
  7. Kyoto University Hospital：Announcement of physician-initiated clinical trials for Parkinson’s disease